The OIG Schizophrenia Audit: Compliance Risks in 2026

In March, the Department of Health and Human Services Office of Inspector General (HHS-OIG), issued a report titled “Nursing Homes Inappropriately Diagnosed Residents with Schizophrenia to Mask the Misuse of Antipsychotic Drugs.” It reveals a systemic upcoding trend designed to protect Star Ratings and avoid federal scrutiny. It also signals a new wave of Skilled Nursing Facilities (SNF) schizophrenia audits in 2026.

In this article, we’ll look at what OIG found, how The Centers for Medicare & Medicaid Services (CMS) has responded, what this means for nursing homes, and why consultant pharmacists are the first line of defense against audit exposure.

Federal Watchdog Uncovers False Schizophrenia Diagnoses in Nursing

In practice, a schizophrenia audit is a CMS-initiated review that cross-references a facility’s MDS schizophrenia diagnoses against Medicare and Medicaid billing records to determine whether the diagnosis was clinically supported or used to mask antipsychotic use. OIG reviewed 40 nursing home inspections and found a troubling pattern. Facilities were misdiagnosing residents with schizophrenia to justify giving them antipsychotic drugs.

Nursing homes are rated in part on how frequently they use antipsychotics—medications that can sedate patients and pose serious risks for elderly residents with dementia. However, residents with schizophrenia are excluded from that measure.

By falsely coding schizophrenia, facilities concealed their actual drug use, maintained higher star ratings, and circumvented the oversight designed to protect residents. The OIG report exposed this as a case of inappropriate antipsychotic use on a systemic level.

CMS Responds with Claims-Based Verification

That loophole has been closed. Effective January 2026, the CMS antipsychotic quality measure schizophrenia exclusion has been fundamentally changed.

Previously, facilities self-reported schizophrenia diagnoses on the Minimum Data Set (MDS), and CMS accepted them at face value. Now, they are cross-referencing diagnoses against Medicare and Medicaid billing records. If a facility codes a resident as having schizophrenia but there’s no matching diagnosis in the claims data, that resident counts toward the antipsychotic quality measure.

CMS estimates this will raise the national reported rate of antipsychotic use from 14.6% to nearly 17%, reflecting a more accurate picture of prescribing practices.

What This Means for Your Facility

Facilities that fail a schizophrenia audit face immediate penalties:

• Overall quality measure rating downgraded to one star for six months
• Overall Star Rating drops by one star
• Long-stay antipsychotic measure suppressed for 12 months
• Short-stay quality measure rating suppressed for six months

Facilities notified of an upcoming audit have one additional option: self-disclosure. CMS will consider reduced penalties for facilities that proactively admit to coding errors before the audit begins. While this does not eliminate consequences, it can meaningfully limit the rating damage outlined above. A publicized rating downgrade, visible to families and referral partners on Care Compare, can have lasting effects on census and revenue.

In addition, nursing homes flagged during an OIG audit face potential False Claims Act liability, civil monetary penalties, and in serious cases, exclusion from Medicare and Medicaid participation. 

Facilities that have relied on schizophrenia exclusions to manage their antipsychotic quality measure scores should treat this as an immediate call to action, not a future compliance consideration.

Consultant Pharmacists as the First Line of Defense

Far from simply fulfilling federal and state mandates, consultant pharmacists can drive measurable improvements in resident safety, reduce survey citation risk, and elevate overall quality of care. They review medication regimens and flag the clinical and regulatory vulnerabilities that lead to citations and Star Rating downgrades, before a surveyor does. 

This is critical, because when inappropriate antipsychotic use penalties apply under the updated quality measure, the cost to your facility, both financially and reputationally, can be significant.

That’s where the right pharmacy partner makes the difference. Clarest’s consultant pharmacists are embedded members of your interdisciplinary team. In practice, this means:

• Medication Regimen Reviews that flag inappropriate antipsychotic use before it affects your Star Rating
• Gradual Dose Reduction (GDR) protocols led in coordination with prescribers to reduce reliance on antipsychotics where clinically appropriate
• Admission and interim medication reviews that catch high-risk antipsychotic use before it appears on an MDS assessment
• QAPI and regulatory compliance support so your facility maintains the documentation CMS expects during a survey
• Staff education on clinical updates, regulatory changes, and long-term care best practices

As audits intensify in 2026, those who act early and strategically will address these issues before they escalate.

Contact us today to learn how Clarest’s consultant pharmacists can protect your residents and your rating.